Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent mllerian carcinoma

Clinical Ovarian Cancer

Volumn 4, Issue 1, 2011, Pages 26-33

  Horowitz, Neil S ^a   Penson, Richard T ^b   Duda, Dan G ^b   Di Tomaso, Emmanuelle ^b   Boucher, Yves ^b   Ancukiewicz, Marek ^b   Cohen, Kenneth S ^b   Berlin, Suzanne ^a   Krasner, Carolyn N ^b   Moses, Marsha A ^c   Jain, Rakesh K ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Bevacizumab; Biomarkers; Mullerian cancer

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BIOLOGICAL MARKER; ENOXAPARIN; GELATINASE A; GEMCITABINE; OXALIPLATIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENZYME ACTIVITY; FATIGUE; FEMALE; GYNECOLOGIC CANCER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIVER TOXICITY; MONOCYTE; MUCOSA INFLAMMATION; MULLERIAN CARCINOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; RHINORRHEA; STEM CELL; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 80052514816     PISSN: 19414390     EISSN: 19414404     Source Type: Journal    
DOI: 10.1016/j.cloc.2011.04.003     Document Type: Article

References (38)

1. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study Gynecol Oncol 101 2006 436 440 (Pubitemid 43729968)
2. D.G. Mutch, M. Orlando, and T. Goss Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 2007 2811 2818 (Pubitemid 47123191)
3. J. Pfisterer, M. Plante, and I. Vergote Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 2006 4699 4707 (Pubitemid 46630933)
4. T. Thigpen The role of gemcitabine in first-line treatment of advanced ovarian carcinoma Semin Oncol 33 2006 26 32 (Pubitemid 43729192)
5. J.L. Misset, P. Vennin, and P.H. Chollet Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients Ann Oncol 12 2001 1411 1415 (Pubitemid 33100247)
6. P. Harnett, M. Buck, and P. Beale Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study Int J Gynecol Cancer 17 2007 359 366 (Pubitemid 46426756)
7. F. Raspagliesi, F. Zanaboni, and F. Vecchione Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane Oncology 67 2004 376 381
8. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
9. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
10. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
11. J.A. Nagy, E.M. Masse, and K.T. Herzberg Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation Cancer Res 55 1995 360 368
12. B.C. Cooper, J.M. Ritchie, and C.L. Broghammer Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clin Cancer Res 8 2002 3193 3197 (Pubitemid 35155030)
13. R.A. Burger, M.W. Sill, and B.J. Monk Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171 (Pubitemid 350237599)
14. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186 (Pubitemid 350232248)
15. A.A. Garcia, H. Hirte, and G. Fleming Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
16. A.X. Zhu, L.S. Blaszkowsky, and D.P. Ryan Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma J Clin Oncol 24 2006 1898 1903 (Pubitemid 46638989)
17. T.T. Batchelor, A.G. Sorensen, and E. di Tomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95 (Pubitemid 46075199)
18. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
19. R.K. Jain, D.G. Duda, and J.W. Clark Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 2006 24 40 (Pubitemid 43108832)
20. C.G. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026
21. A.X. Zhu, D.V. Sahani, and D.G. Duda Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
22. R.K. Jain, D.G. Duda, and C.G. Willett Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 2009 327 338
23. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147 (Pubitemid 38524883)
24. D.G. Duda, K.S. Cohen, and D.T. Scadden A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood Nat Protoc 2 2007 805 810 (Pubitemid 46745577)
25. R. Roy, G. Louis, and K.R. Loughlin Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species Clin Cancer Res 14 2008 6610 6617
26. C.R. Genovese, K. Roeder, and L. Wasserman False discovery control with p-value weighting Biometrika 93 2006 509 524 (Pubitemid 44599847)
27. A. Pohl, W. Zhang, and Y. Ning Targeting metastatic colorectal cancer in 2008: a long way from 5-FU Oncology (Williston Park) 22 2008 456 462
28. R.K. Jain, R.T. Tong, and L.L. Munn Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model Cancer Res 67 2007 2729 2735 (Pubitemid 46548961)
29. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 2001 987 989 (Pubitemid 32937367)
30. R.K. Jain Taming vessels to treat cancer Sci Am 298 2008 56 63 (Pubitemid 351182556)
31. J.M. Ebos, C.R. Lee, and W. Cruz-Munoz Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
32. M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
33. U.A. Matulonis, N.S. Horowitz, and S.M. Campos Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer J Clin Oncol 26 2008 5761 5766
34. A.G. Taghian, R. Abi-Raad, and S.I. Assaad Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications J Clin Oncol 23 2005 1951 1961 (Pubitemid 46211374)
35. J.M. Ebos, C.R. Lee, and J.G. Christensen Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proc Natl Acad Sci U S A 104 2007 17069 17074 (Pubitemid 350210993)
36. L. Xu, D.G. Duda, and E. di Tomaso Direct evidence that bevacizumab, an antivascular endothelial growth factor antibody, upregulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer Cancer Res 69 2009 7905 7910
37. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
38. D.G. Duda, M. Ancukiewicz, and R.K. Jain Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol 28 2009 183 185